Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?

While CellaVision AB (publ) (STO:CEVI) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the OM, rising to highs of kr396 and falling to the lows of kr294. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether CellaVision's current trading price of kr313 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at CellaVision’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

Check out our latest analysis for CellaVision

What is CellaVision worth?

According to my valuation model, CellaVision seems to be fairly priced at around 2.9% below my intrinsic value, which means if you buy CellaVision today, you’d be paying a fair price for it. And if you believe the company’s true value is SEK322.66, then there’s not much of an upside to gain from mispricing. Although, there may be an opportunity to buy in the future. This is because CellaVision’s beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company’s shares will likely fall by more than the rest of the market, providing a prime buying opportunity.

Can we expect growth from CellaVision?

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. CellaVision's earnings over the next few years are expected to increase by 72%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? It seems like the market has already priced in CEVI’s positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?

Are you a potential investor? If you’ve been keeping an eye on CEVI, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it’s worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

If you'd like to know more about CellaVision as a business, it's important to be aware of any risks it's facing. You'd be interested to know, that we found 1 warning sign for CellaVision and you'll want to know about it.

If you are no longer interested in CellaVision, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.